Reuters logo
7 months ago
BRIEF-Merck & Co Inc gets FDA acceptance of supplemental biologics license application for Keytruda in combination with chemotherapy
January 10, 2017 / 9:21 PM / 7 months ago

BRIEF-Merck & Co Inc gets FDA acceptance of supplemental biologics license application for Keytruda in combination with chemotherapy

Jan 10 (Reuters) - Merck & Co Inc :

* Merck receives fda acceptance of supplemental biologics license application for keytruda (pembrolizumab) in combination with chemotherapy for first-line treatment of metastatic non-squamous non-small cell lung cancer

* Merck & co inc - fda granted priority review with a pdufa, or target action, date of may 10, 2017

* Merck & Co Inc- SBLA will be reviewed under fda's accelerated approval program Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below